Aptamer Market to Register CAGR of Over 20.0% from 2017 to 2025

The global aptamer market was valued at approximately US$ 1.0 Bn in 2016 is projected to register cumulative annual growth rate (CAGR) of over 20.0% from 2017 to 2025, according to a new report published by Transparency Market Research (TMR) titled “Aptamer Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025”. The report suggests that surge in interest of research activity in the field of aptamer technology is likely to spur the demand of aptamer in the coming years (2017 to 2025). As key players introduce their new aptamer services for different application in developed markets such a North America and Western Europe, these regions are likely to account for dominating share of the global aptamer market. Demands for new diagnostic assay and increasing research activity in emerging markets such as China and Japan is likely to boost growth of Asia Pacific aptamer market at a CAGR of around 21.0% from 2017 to 2025.

Request for Sample Copy of Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1335

Inadequate Regulatory Policies and Ethical Issues Related To Aptamer Development Can Restrain Global Market Expansion

Aptamer can be used as alternative to antibodies for various application. There is no formal regulatory guideline, which specifically addresses the quality expectation of aptamers. The regulatory expectation of aptamer-based drugs is still evolving. Several countries in Europe have tedious documentation processes for starting clinical trials of aptamers. For example, in Europe, the EU Clinical Trial Directive 2001/20/ EC is mandatory for initiation of aptamer clinical trials. However, the region has not developed any oligonucleotide specific guideline that can address the general requirements for the quality of aptamer clinical trials. Moreover, lack of universal rules for the application of aptamers in bioassays, which is well established when working with antibodies, restrains growth of global aptamer market.

Other Selection Techniques (e.g. X- Aptamer, MARAS etc.) to Lose Market Share

The report offers detailed segmentation of global aptamers market based on material type, selection technique and applications. Among the selection technique studied, SELEX technique segment is poised to account for leading share of the global market during the forecast period from 2017 to 2025. SELEX technique is likely to get boost for the modification of existing SELEX process, and available of the new updated SELEX technique like CE-SELEX, M- SELEX etc. which overcome the certain limitation for aptamer selection. The other technique (X-aptamer, MARAS technique etc.) segment is anticipated to lose its market share during the forecast period, and is expected to hold a share of ~18.0% by 2025 from ~21% in 2016. Availability of upgraded SELEX technique and lack of selection of high affinity ligands as compare to SELEX technique are factors likely to hamper this segment.

Enquiry for discount on this report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1335

Diagnostics & Research: Top Two Application Areas of Aptamer

Among applications, research segment is projected to hold dominant share of global aptamer market during the forecast period and is likely to expand at CAGR more than 21.0% from 2017 to 2025. Major factors responsible for the dominance of this segment are efforts by several key players to develop new aptamers for research and development applications. For example, Aptagen, LLC has developed aptabodies (patent pending) that overcome the limitation of traditional pharmaceutical drug discovery process. The Aptabody technology demands shorter development time and offers effective Adsorption, Distribution, Metabolism and Excretion (ADME) properties due to unique chemical properties. Aptabodies are formed by hybridization of two DNA aptamers and allow detection of human thrombin effectively compared to traditional aptamers. In addition, aptabodies represent new area of development for next generation pharmaceuticals with improved pharmacokinetics and pharmacodynamic. Diagnostics segment, accounted for more than 30.0% share of global aptamer market in 2016, in terms of value. It is anticipated to have substantial growth and account for approximately 33.8% of market share by 2025.

Asia Pacific to Resister Exponential Growth and Offer Huge Incremental Opportunity

In terms of value, North America was leading contributor in global aptamer market in 2016. High level of research activity in the U.S. is one of the contributing factor for major share of the North America market. Furthermore, presence of several key players such as Aptagen, Inc., Regado Biosciences, Inc. and Somalogic, Inc. has resulted in increased investment in research and development of novel aptamers. Thus, presence of these players would help the aptamers market in North America to grow rapidly during the forecast period Pharmaceutical research and development spending in emerging markets such as China and India are rising, which is fueling the expansion of Asia Pacific aptamer market. Regaining economic growth in Latin American markets such as Brazil is augmenting research and development activity, spending is increasing in diagnosis and treatment of various diseases in this region. This factor is likely to propel Latin America cardiovascular drugs market at CAGR of 19.0% from 2017 to 2025.

Request for the TOC of the Report @ https://www.transparencymarketresearch.com/report-toc/1335

Key Players such as Somalogic, Inc., Aptagen, Inc, and Aptamer Group Limited are Likely to Continue to Lead the Global Aptamer Market

The report also provide profiles of leading players operating in global aptamer market include AM Biotech, Aptagen, LLC., Aptamer Group, Aptamer Sciences, Inc., Base Pair Biotechnologies, CD Genomics, NeoVentures Biotechnology Inc., NAXXON Pharma, Aptus Biotech, TriLink BioTechnologies, LLC., and Pfizer Inc. Expansion of aptamer based products portfolio through improving existing drugs and developing new drug molecules is one of the key strategy adopted by many key players, recent developing drugs such as NOX-E36 for treating type 2 diabetes by NAXXON Pharma and other key players reflect these strategies.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com

Leave a Reply

Your email address will not be published. Required fields are marked *